Cytoxan

(redirected from cyclophosphamide)
Also found in: Dictionary, Medical, Acronyms, Wikipedia.
Related to cyclophosphamide: vincristine

Cytoxan

(sītŏk`sĭn), trade name for the drug cyclophosphamide, used to inhibit growth of tumors and rapidly proliferating cells. It is used in the treatment of leukemia, Hodgkin's disease, and lymphosarcoma and other solid tumors. A drug of great specificity, Cytoxan is activated in the body by the enzymes in certain types of tumors. Because it is also activated in such tissues as blood plasma and liver, it is a highly toxic substance. Nevertheless, it is a potent and useful chemotherapeutic agent.
The Columbia Electronic Encyclopedia™ Copyright © 2013, Columbia University Press. Licensed from Columbia University Press. All rights reserved. www.cc.columbia.edu/cu/cup/
References in periodicals archive ?
The placental weight was decreased in those groups that received cyclophosphamide. But only the group receiving cyclophosphamide and chlorophyllin in the lowest dose showed a statistically significant difference.
Toxic effect of cyclophosphamide on sperm morphology, testicular histology and blood oxidant-antioxidant balance, and protective roles of lycopene and ellagic acid.
Cyclophosphamide, mesna, hexade-cyltrimethylammonium bromide, o-dianisidine hydrochloride, and Turk solutions were purchased from Sigma (USA).
Acute myelopathies and vasculitic neuropathies should be treated with intravenous glucocorticoids, plasma exchange and cyclophosphamide as partial to complete recovery may be expected.
Permanent hair loss is reported with certain drugs such as cyclophosphamide and busulfan.
Breast cancer one of the most frequent cancer type among females and treatment involves various combination therapies in which AC is one of most frequent therapy prescribed by physicians especially for the treatment of breast cancer.7 AC stands for Adriamycin (doxorubicin) and Cyclophosphamide which is given in cycles which are repeated every 21 days and usually four cycles are given.
"Overall survival at 72 months was 86 percent after transplant versus 51 percent after cyclophosphamide," said the report.
In Sections 3 and 4, preferences were ascertained for maintenance Cyclophosphamide versus Rituximab, maintenance Azathioprine versus Mycophenolate Mofetil use, Trimethoprim-Sulfamethoxazole use, and clinical tools used for assessing initial and relapse disease activity.
Cyclophosphamide, another kind of alkylating agents, was also reported to induce SOS in a synergistic effect with total body irradiation [4].